US · Healthcare · Biotechnology
EPS came in at 0.36 against a street estimate of -0.04 — a beat of 1000.0%.
Analysts rate Corcept Therapeutics Incorporated a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $135.25.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.24% |
| Ingalls & Snyder LLC | 7.04% |
| Renaissance Technologies Corp | 5.26% |
| Vanguard Portfolio Management, LLC | 4.46% |
| Vanguard Capital Management, LLC | 3.77% |
| Parallel Advisors, LLC | 3.68% |
| State Street Corp | 2.96% |
| FMR Inc | 2.95% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-29 |
| Company announcement · Q2 2026 | 2026-06-17 |
| Company announcement · Q2 2026 | 2026-06-03 |
| Board / officer change · Q2 2026 | 2026-05-28 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-17 |
| Annual report FY2025 | 2026-02-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Corcept Therapeutics Incorporated — free to start.
Google PlayApp StoreData updated 2026-08-05.